{
    "symbol": "SPPI",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 11:44:06",
    "content": " Since the beginning of the year we have continued to focus on the following three key business objectives; one, gaining FDA approvals and further advancing our two late stage assets; two, reducing our operating cash burn; and three, ensuring we are prepared to successfully launch both products. Your line is now open. Your line is now open. As it relates to efla, I think that one assuming an approval or an action date that's positive on the 9th of September, then you would have the cycle time of call it five to eight weeks for drugs to get in channel. If you're asking about -- specifically, I think that conversation post approval would need to be had, assuming it's an accelerated approval in the U.S. to see what the receptivity is there for Europe. Your line is now open. Your line is now open. And obviously, we monitored carefully the treatment landscape as it is evolving and we think we're in a good position and patient, let's face it, needs options, and we certainly believe that Pozi would present a very attractive option for patients. Your line is now open."
}